ctDNA-Informed Management of Early-Stage Rectal Cancer (NCT07209215)
ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.
Who can join: Review the eligibility criteria below.
Location: University of California Davis Comprehensive Cancer Center — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California Davis Comprehensive Cancer Center — Sacramento, California
📞 Contact the Study Coordinator
Phone: (916) 382-6970
Email: OCRReferral@health.ucdavis.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rectal Adenocarcinoma
- Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma — Tampa, Florida
- ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer — Portland, Oregon
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors — Hartford, Connecticut
- Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer — Houston, Texas
- Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer — Portland, Oregon
Explore by condition: All Rectal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.